Did you know?

Track Citius Pharmaceuticals Inc (CTXR) Stock Price, Quote, latest community messages, chart, news and other stock related information.Find the latest news headlines from Citius Pharmaceuticals, Inc. Common Stock (CTXR) at Nasdaq.com.Citius Pharmaceuticals, Inc. Common Stock (CTXR) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Convert Citius Pharmaceuticals Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. Select a currency. USD. NASDAQ: Citius Pharmaceuticals Inc ( CTXR) = 0.78 USD. Provided by Alpha Vantage.Citius Pharmaceuticals (NASDAQ:CTXR) announces that the independent Data Monitoring Committee (DMC) for the Mino-Lok Phase 3 Pivotal Superiority Trial has recommended to proceed with the trial as ...Based on analysts offering 12 month price targets for CTXR in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . May 12, 2023 · Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care ... Latest SEC filings for Citius Pharmaceuticals, Inc. (CTXR).A high-level overview of Citius Pharmaceuticals, Inc. (CTXR) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.CRANFORD, N.J., June 26, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first ...Citius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company. Published. May 18, 2022.In the case of Citius Pharmaceuticals (NASDAQ:CTXR), a specialty pharmaceutical company dedicated to developing and commercializing novel critical care drug products, the company understands how ...Telehealth at Nebraska Medicine. Across the country, telehealth encompasses a broad variety of technologies and tactics to deliver virtual medical, health, and education …("Citius" or the "Company") (NasdaWith the business potentially at an important milestone, we t Mar 30, 2023 · CRANFORD, N.J., March 30, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first ... Find the latest Insider Activity data for Citius Pharmaceuticals, Inc. Common Stock (CTXR) at Nasdaq.com. View the latest CTXR earnings date, analysts forecasts, CRANFORD, N.J., June 26, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first ...At the end of Q2 2023, CTXR held $33.3 million in cash and equivalents, with total current assets reaching $41.1 million. This was set against a net loss of $8.5 million. They've actually trimmed ... Citius Pharmaceuticals Inc stock price (CTXR) NASDAQ: CTXR. Buyi

Dec 1, 2023 · CTXR Citius Pharmaceuticals Inc Citius Pharmaceuticals Announces $15 Million Registered Direct Offering Feb 9, 2022 · With the business potentially at an important milestone, we thought we'd take a closer look at Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) future prospects. Citius Pharmaceuticals, Inc., a ... Resubmission to FDA planned for early 2024 . CRANFORD, N.J., Sept. 8, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) is pleased to announce the Company has received additional guidance from the U.S. Food and Drug Administration (FDA) regarding the planned resubmission of the …

NASDAQ: CTXR CLICK TO EDIT MASTER TITLE STYLE This presentation has been prepared by Citius Pharmaceuticals, Inc. (the “Company”)for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation byNov 30, 2023 · 1 Wall Street research analysts have issued 1 year target prices for Citius Pharmaceuticals' stock. Their CTXR share price targets range from $4.00 to $4.00. On average, they anticipate the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 415.9% from the stock's current price. …

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Jul 29, 2023 · CRANFORD, N.J., July 29, 2023 /PRNews. Possible cause: Health Care Sector Update for 09/08/2023: CTXR, BIOC, GILD, NVOS September .